uniQure N.V. (0EE0.L)
USD 14.51
(-1.73%)
USD 14.51
(-1.73%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 15.84 Million USD | -85.12% |
| 2022 | 106.48 Million USD | -79.68% |
| 2021 | 524 Million USD | 1296.82% |
| 2020 | 37.51 Million USD | 415.23% |
| 2019 | 7.28 Million USD | -35.48% |
| 2018 | 11.28 Million USD | -13.91% |
| 2017 | 13.1 Million USD | -47.78% |
| 2016 | 25.09 Million USD | 143.57% |
| 2015 | 10.3 Million USD | 80.87% |
| 2014 | 5.69 Million USD | 40.19% |
| 2013 | 4.06 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 2.28 Million USD | -79.44% |
| 2024 Q1 | 8.48 Million USD | 26.85% |
| 2024 Q2 | 11.12 Million USD | 31.13% |
| 2023 Q3 | 1.4 Million USD | -41.91% |
| 2023 Q4 | 6.68 Million USD | 375.41% |
| 2023 FY | 15.84 Million USD | -85.12% |
| 2023 Q1 | 5.32 Million USD | -94.82% |
| 2023 Q2 | 2.42 Million USD | -54.52% |
| 2022 FY | 106.48 Million USD | -79.68% |
| 2022 Q2 | 497 Thousand USD | -72.27% |
| 2022 Q1 | 1.79 Million USD | -96.89% |
| 2022 Q4 | 102.74 Million USD | 6990.75% |
| 2022 Q3 | 1.44 Million USD | 191.55% |
| 2021 Q2 | 463.86 Million USD | 102073.57% |
| 2021 Q4 | 57.69 Million USD | 2800.5% |
| 2021 Q3 | 1.98 Million USD | -99.57% |
| 2021 Q1 | 454 Thousand USD | -98.67% |
| 2021 FY | 524 Million USD | 1296.82% |
| 2020 Q1 | 104 Thousand USD | -96.04% |
| 2020 Q3 | 1.78 Million USD | 16.55% |
| 2020 Q4 | 34.08 Million USD | 1805.31% |
| 2020 FY | 37.51 Million USD | 415.23% |
| 2020 Q2 | 1.53 Million USD | 1375.96% |
| 2019 Q3 | 1.04 Million USD | -57.72% |
| 2019 Q2 | 2.47 Million USD | 117.78% |
| 2019 Q1 | 1.13 Million USD | -29.35% |
| 2019 FY | 7.28 Million USD | -35.48% |
| 2019 Q4 | 2.62 Million USD | 150.96% |
| 2018 Q3 | 3.14 Million USD | 3.21% |
| 2018 Q1 | 3.47 Million USD | 34.6% |
| 2018 Q4 | 1.6 Million USD | -48.92% |
| 2018 FY | 11.28 Million USD | -13.91% |
| 2018 Q2 | 3.05 Million USD | -12.31% |
| 2017 Q4 | 2.58 Million USD | 14.34% |
| 2017 Q3 | 2.26 Million USD | -54.27% |
| 2017 Q2 | 4.94 Million USD | 48.81% |
| 2017 FY | 13.1 Million USD | -47.78% |
| 2017 Q1 | 3.32 Million USD | -63.28% |
| 2016 Q1 | 4.42 Million USD | 19.61% |
| 2016 FY | 25.09 Million USD | 143.57% |
| 2016 Q3 | 7.25 Million USD | 65.48% |
| 2016 Q2 | 4.38 Million USD | -0.87% |
| 2016 Q4 | 9.04 Million USD | 24.69% |
| 2015 FY | 10.3 Million USD | 80.87% |
| 2015 Q4 | 3.69 Million USD | 4.31% |
| 2015 Q1 | 1.19 Million USD | -26.0% |
| 2015 Q3 | 3.54 Million USD | 95.67% |
| 2015 Q2 | 1.81 Million USD | 51.1% |
| 2014 Q2 | 1.42 Million USD | -11.65% |
| 2014 Q3 | 1.27 Million USD | -10.65% |
| 2014 Q4 | 1.62 Million USD | 27.54% |
| 2014 FY | 5.69 Million USD | 40.19% |
| 2014 Q1 | 1.6 Million USD | 24.13% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | 986.15 Thousand USD | 0.0% |
| 2013 Q3 | 1.74 Million USD | 76.93% |
| 2013 Q4 | 1.29 Million USD | -25.7% |
| 2013 FY | 4.06 Million USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Imunon, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 338.205% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -352.657% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 49.301% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | 40.935% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 96.033% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -84.801% |
| bluebird bio, Inc. | 29.49 Million USD | 46.289% |
| Blueprint Medicines Corporation | 249.38 Million USD | 93.647% |
| Cara Therapeutics, Inc. | 20.96 Million USD | 24.442% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 232.28 Million USD | 93.179% |
| Editas Medicine, Inc. | 78.12 Million USD | 79.72% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 86.381% |
| Geron Corporation | 237 Thousand USD | -6584.81% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 87.53% |
| Illumina, Inc. | 4.5 Billion USD | 99.648% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -1232.464% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 99.894% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 99.582% |
| Myriad Genetics, Inc. | 678.4 Million USD | 97.665% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.16% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 98.726% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 97.392% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.989% |
| Waters Corporation | 2.95 Billion USD | 99.464% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.839% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.963% |
| Biogen Inc. | 9.83 Billion USD | 99.839% |
| Nektar Therapeutics | 90.12 Million USD | 82.42% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 99.66% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 99.345% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 91.01% |
| Evolus, Inc. | 202.08 Million USD | 92.16% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.879% |
| FibroGen, Inc. | 147.75 Million USD | 89.277% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 99.768% |
| OPKO Health, Inc. | 863.49 Million USD | 98.165% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 99.133% |
| Exelixis, Inc. | 1.83 Billion USD | 99.134% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | 56.325% |
| Zoetis Inc. | 8.54 Billion USD | 99.815% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 94.145% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 97.989% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 96.716% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 98.089% |
| Insmed Incorporated | 305.2 Million USD | 94.809% |
| TG Therapeutics, Inc. | 233.66 Million USD | 93.22% |
| Incyte Corporation | 3.69 Billion USD | 99.571% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 98.49% |